Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adicet Bio, Inc.TORC · Entity 6860 | Director | June 03, 2020 | June 05, 2020 |
| Solid Biosciences Inc.SLDB · Entity 4915 | Director | June 10, 2026 | June 11, 2026 |
| Tessera Defense & Homeland Security Inc.PHGE · Entity 8384 | Director | March 01, 2023 | March 03, 2023 |
| Unity Biotechnology, Inc.UBX · Entity 77428 | CFO & Head of Corp. Dev. | April 02, 2025 | April 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adicet Bio, Inc.
Report date June 03, 2020 · Filed June 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.23 · Expires 2030-06-02 | Direct | 14,414 |
Reported balance
After 2020-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-03 · Grant · Acquired 14,414 · Balance 14,414 F1: This option was granted on June 3, 2020 with respect to 14,414 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 3, 2020 with respect to 14,414 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
Solid Biosciences Inc.
Report date June 10, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.61 · Expires 2036-06-10 | Direct | 77,500 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 77,500 · Balance 77,500 F1: This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.
Tessera Defense & Homeland Security Inc.
Report date March 01, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock Options - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $0.40 · Expires 2033-03-01 | Direct | 41,000 |
Reported balance
After 2023-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-01 · Grant · Acquired 41,000 · Balance 41,000 F1: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 1, 2024, and the remainder vesting in 12 equal quarterly installments over three years. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 1, 2024, and the remainder vesting in 12 equal quarterly installments over three years.
Unity Biotechnology, Inc.
Report date April 02, 2025 · Filed April 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 98,905 |
Reported balance
After 2025-04-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-04-02 · Sale · Disposed 21,867 · Balance 98,905 F1: Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading instruction to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2: Includes Restricted Stock Units which vest over time measured from the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading instruction to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units.
F2: Includes Restricted Stock Units which vest over time measured from the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Inozyme Pharma, Inc.
Report date July 01, 2025 · Filed July 03, 2025
Section 16 reporting ended · disclosed 2025-07-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.77 · Expires 2030-05-27 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-01 · Disposition to issuer · Disposed 28,368 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger"). F2: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger").
F2: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 11, 2026 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $6.61 | $0.00 |
DisclosureSEC source: 0001193125-26-267494 · ownership.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2036-06-10 F1 · derivative.exercise_date: This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 19:04 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | Disposition to issuerStock Option (Right to Buy) · Derivative | 28,368 | Not disclosed Strike: $2.77 | Not disclosed |
DisclosureSEC source: 0000950170-25-094093 · ownership.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,368 shares Expires 2030-05-27 F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger"). F2 · price: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 20:25 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0000950170-25-086232 · ownership.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2035-06-12 F1 · derivative.exercise_date: This option was granted on June 12, 2025 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| April 02, 2025 Filed Apr 3, 2025 16:16 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | SaleCommon Stock, $0.0001 par value | 21,867 | $1.03 | $22,523.01 |
DisclosureSEC source: 0000950170-25-050410 · ownership.xml · nonDerivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · CFO & Head of Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,905 F1 · kind: Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading instruction to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · balance_after: Includes Restricted Stock Units which vest over time measured from the grant date. Read SEC document |
| March 28, 2025 Filed Mar 31, 2025 16:16 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 106,000 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0000950170-25-047746 · ownership.xml · derivative · entry 2 Sullivan Lynne Marie · CIK 0001727640 · CFO & Head of Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,000 Underlying: Common Stock · 106,000 shares Expires 2035-03-27 F3 · derivative.exercise_date: On January 30, 2024, the Board of Directors granted the Reporting Person an option to purchase 106,000 shares of common stock. The underlying shares vest and become exercisable pursuant to the following schedule: one half of the shares subject to the option vest upon the satisfaction of certain performance criteria, which were met on March 28, 2025, and the remaining shares subject to the option vest in 12 successive, equal monthly installments thereafter until fully vested, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| March 28, 2025 Filed Mar 31, 2025 16:16 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantCommon Stock, $0.0001 par value | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-047746 · ownership.xml · nonDerivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · CFO & Head of Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,772 F1 · shares: On January 30, 2024, the Board of Directors granted the Reporting Person 65,000 Restricted Stock Units ("RSUs") that vest in full upon the satisfaction of certain performance criteria, which were met on March 28, 2025. F2 · balance_after: Includes RSUs that vest over time measured from the grant date. Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 16:35 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | SaleCommon Stock, $0.0001 par value | 153 | $2.23 | $341.19 |
DisclosureSEC source: 0000950170-25-014570 · ownership.xml · nonDerivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · CFO & Head of Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,772 F1 · kind: Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading instruction to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · balance_after: Includes Restricted Stock Units which vest over time measured from the grant date. Read SEC document |
| January 22, 2025 Filed Jan 23, 2025 16:05 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0000950170-25-008315 · ownership.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · CFO & Head of Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2035-01-21 F1 · derivative.exercise_date: The underlying shares vest and become exercisable pursuant to the following schedule: one third of the shares subject to the option vest on December 31, 2025 and the remaining shares subject to the option vest in 24 successive, equal monthly installments thereafter on each monthly anniversary of December 31, 2025 until fully vested on December 31, 2027, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| November 04, 2024 Filed Nov 6, 2024 16:10 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | SaleCommon Stock, $0.0001 par value | 136 | $1.29 | $175.44 |
DisclosureSEC source: 0000950170-24-122295 · ownership.xml · nonDerivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · CFO & Head of Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,925 F1 · kind: Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading instruction to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · balance_after: Includes Restricted Stock Units which vest over time measured from the grant date. Read SEC document |
| August 02, 2024 Filed Aug 6, 2024 17:00 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | SaleCommon Stock, $0.0001 par value | 139 | $1.53 | $212.67 |
DisclosureSEC source: 0000950170-24-091964 · ownership.xml · nonDerivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · CFO & Head of Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,061 F1 · kind: Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading instruction to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · balance_after: Includes Restricted Stock Units which vest over time measured from the grant date. F3 · balance_after: Represents adjusted total that includes an aggregate of 23,515 shares purchased under the Unity Biotechnology, Inc. 2018 Employee Stock Purchase Plan on May 15, 2023 and May 15, 2024 in transactions exempt from reporting pursuant to Rule 16b-3(c). Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 16:05 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | SaleCommon Stock, $0.0001 par value | 324 | $1.40 | $453.60 |
DisclosureSEC source: 0000950170-24-077848 · ownership.xml · nonDerivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · CFO & Head of Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,685 F1 · kind: Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading instruction to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · balance_after: Includes Restricted Stock Units which vest over time measured from the grant date. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 16:12 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantStock Option (right to buy) · Derivative | 28,000 | $0.00 Strike: $4.40 | $0.00 |
DisclosureSEC source: 0000950170-24-075579 · ownership.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2034-06-17 F1 · derivative.exercise_date: The option was granted on June 18, 2024. The shares underlying the option are scheduled to vest as to 100% of the shares on June 18, 2025, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:10 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 34,400 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0000950170-24-073003 · ownership.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,400 Underlying: Common Stock · 34,400 shares Expires 2034-06-11 F1 · derivative.exercise_date: This option was granted on June 11, 2024 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 16:05 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $6.18 | $0.00 |
DisclosureSEC source: 0001209191-23-037301 · doc4.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2033-06-12 F1 · derivative.exercise_date: The option was granted on June 13, 2023. The shares underlying the option are scheduled to vest as to 100% of the shares on June 13, 2024, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 06, 2023 Filed Jun 9, 2023 01:21 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 9,650 | $0.00 Strike: $6.37 | $0.00 |
DisclosureSEC source: 0000899243-23-015004 · doc4.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,650 Underlying: Common Stock · 9,650 shares Expires 2033-06-06 F1 · derivative.exercise_date: This option was granted on June 6, 2023 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| May 11, 2023 Filed May 12, 2023 20:09 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.77 | $0.00 |
DisclosureSEC source: 0000899243-23-012905 · doc4.xml · derivative · entry 7 Sullivan Lynne Marie · CIK 0001727640 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-02-09 F7 · price: On May 11, 2023, the option originally granted to the Reporting Person on February 9, 2022 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged. F6 · derivative.exercise_date: The underlying shares vest and become exercisable pursuant to the following schedule: One Third of the shares subject to the option vest on February 9, 2023 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 24 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| May 11, 2023 Filed May 12, 2023 20:09 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0000899243-23-012905 · doc4.xml · derivative · entry 6 Sullivan Lynne Marie · CIK 0001727640 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2032-02-09 F7 · price: On May 11, 2023, the option originally granted to the Reporting Person on February 9, 2022 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged. F6 · derivative.exercise_date: The underlying shares vest and become exercisable pursuant to the following schedule: One Third of the shares subject to the option vest on February 9, 2023 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 24 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| May 11, 2023 Filed May 12, 2023 20:09 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 12,333 | $0.00 Strike: $2.77 | $0.00 |
DisclosureSEC source: 0000899243-23-012905 · doc4.xml · derivative · entry 5 Sullivan Lynne Marie · CIK 0001727640 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,333 Underlying: Common Stock · 12,333 shares Expires 2031-06-24 F5 · price: On May 11, 2023, the option originally granted to the Reporting Person on June 24, 2021 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged. F4 · derivative.exercise_date: Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 48-month period commencing on June 24, 2021 (the "Vesting Commencement Date"), so that 100% of the shares become fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| May 11, 2023 Filed May 12, 2023 20:09 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,333 | $0.00 Strike: $41.80 | $0.00 |
DisclosureSEC source: 0000899243-23-012905 · doc4.xml · derivative · entry 4 Sullivan Lynne Marie · CIK 0001727640 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,333 shares Expires 2031-06-24 F5 · price: On May 11, 2023, the option originally granted to the Reporting Person on June 24, 2021 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged. F4 · derivative.exercise_date: Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 48-month period commencing on June 24, 2021 (the "Vesting Commencement Date"), so that 100% of the shares become fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| May 11, 2023 Filed May 12, 2023 20:09 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $2.77 | $0.00 |
DisclosureSEC source: 0000899243-23-012905 · doc4.xml · derivative · entry 3 Sullivan Lynne Marie · CIK 0001727640 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-08-01 F3 · price: On May 11, 2023, the option originally granted to the Reporting Person on August 1, 2020 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged. F2 · derivative.exercise_date: The underlying shares vest and become exercisable pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vested on August 1, 2021 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| May 11, 2023 Filed May 12, 2023 20:09 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | Disposition to issuerStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $99.60 | $0.00 |
DisclosureSEC source: 0000899243-23-012905 · doc4.xml · derivative · entry 2 Sullivan Lynne Marie · CIK 0001727640 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2030-08-01 F3 · price: On May 11, 2023, the option originally granted to the Reporting Person on August 1, 2020 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged. F2 · derivative.exercise_date: The underlying shares vest and become exercisable pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vested on August 1, 2021 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| May 11, 2023 Filed May 12, 2023 20:09 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $2.77 Strike: $2.77 | $110,800.00 |
DisclosureSEC source: 0000899243-23-012905 · doc4.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-05-11 F1 · derivative.exercise_date: The underlying shares vest and become exercisable pursuant to the following schedule: One-eighth of the shares subject to the option vest in successive, equal quarterly installments starting on August 11, 2023, subject to the Reporting Person's continued service to Issuer through the applicable vesting date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:01 UTC | Tessera Defense & Homeland Security Inc. PHGE · Entity 8384 | GrantCommon Stock Options - Right to Buy · Derivative | 41,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001213900-23-017212 · ownership.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 Underlying: Common Stock · 41,000 shares Expires 2033-03-01 F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 1, 2024, and the remainder vesting in 12 equal quarterly installments over three years. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 23:07 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 9,650 | $0.00 Strike: $6.47 | $0.00 |
DisclosureSEC source: 0000899243-22-038682 · doc4.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,650 Underlying: Common Stock · 9,650 shares Expires 2032-12-13 F1 · derivative.exercise_date: This option was granted on December 13, 2022 and vests in full on the one-year anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| November 18, 2022 Filed Nov 21, 2022 17:26 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0000899243-22-036537 · doc4.xml · derivative · entry 2 Sullivan Lynne Marie · CIK 0001727640 · CFO & Head of Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-11-18 F5 · derivative.exercise_date: The underlying shares vest and become exercisable pursuant to the following schedule: One-eighth of the shares subject to the option vest in successive, equal quarterly installments starting on February 18, 2023, subject to the Reporting Person's continued service to Issuer through the applicable vesting date. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 07:51 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantStock Option (right to buy) · Derivative | 9,367 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001209191-22-036569 · doc4.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,367 Underlying: Common Stock · 9,367 shares Expires 2032-06-09 F1 · derivative.exercise_date: The option was granted on June 10, 2022. The shares underlying the option are scheduled to vest as to 100% of the shares on June 10, 2023, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:13 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 51,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001209191-22-035465 · doc4.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Underlying: Common Stock · 51,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: This option was granted on June 7, 2022 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| May 15, 2022 Filed Nov 21, 2022 17:26 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | OtherCommon Stock, $0.0001 par value | 925 | $6.89 | $6,373.25 |
DisclosureSEC source: 0000899243-22-036537 · doc4.xml · nonDerivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · CFO & Head of Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,009 F1 · kind: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Unity Biotechnology, Inc. 2018 Employee Stock Purchase Plan (the ESPP). The acquisition of those 925 shares was also exempt pursuant to Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on May 15, 2022. F3 · balance_after: Includes RSUs which vest over time measured from the grant date. F4 · balance_after: Reflects a 1-for-10 reverse stock split of the Issuer's common stock, effected by the Issuer on October 19, 2022, which was exempt from reporting pursuant to Rule 16a-9. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 21:28 UTC | Tessera Defense & Homeland Security Inc. PHGE · Entity 8384 | GrantCommon Stock Options - Right to Buy · Derivative | 20,500 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001213900-22-016980 · ownership.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2032-03-29 F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 29, 2023, and the remainder vesting in 12 equal quarterly installments over three years. Read SEC document |
| February 09, 2022 Filed Feb 15, 2022 17:17 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0000899243-22-006446 · doc4.xml · derivative · entry 2 Sullivan Lynne Marie · CIK 0001727640 · CFO & Head of Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-02-09 F3 · derivative.exercise_date: The underlying shares vest and become exercisable pursuant to the following schedule: One Third of the shares subject to the option vest on February 9, 2023 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 24 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| February 09, 2022 Filed Feb 15, 2022 17:17 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantCommon Stock, $0.0001 par value | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-006446 · doc4.xml · nonDerivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · CFO & Head of Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,785 F1 · shares: Represents Restricted Stock Units ("RSUs") one third of which vests on February 9, 2023 with the remaining RSUs vesting in equal quarterly installments over a two year period thereafter. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F2 · balance_after: Includes RSUs which vest over time measured from the grant date. Also includes 5,952 shares of Common Stock of the Issuer purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 13:53 UTC | Tessera Defense & Homeland Security Inc. PHGE · Entity 8384 | PurchaseCommon Stock Warrant · Derivative | 9,375 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001213900-21-039439 · ownership.xml · derivative · entry 2 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,375 Underlying: Common Stock · 9,375 shares Expires 2027-01-28 F1 · price: The common stock and common stock warrant were acquired in the issuer's registered direct offering of units, in which each unit consisted of one share of common stock and one common stock warrant to purchase 0.75 of a share of common stock, at a price of $4.00 per unit. The price paid per unit is reflected in Table I. F2 · derivative.exercise_date: The common stock warrant will be exercisable six months after the date of issuance, at an exercise price of $5.00 per share and will expire five years from the date such warrant first becomes exercisable. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 13:53 UTC | Tessera Defense & Homeland Security Inc. PHGE · Entity 8384 | PurchaseCommon Stock | 12,500 | $4.00 | $50,000.00 |
DisclosureSEC source: 0001213900-21-039439 · ownership.xml · nonDerivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · price: The common stock and common stock warrant were acquired in the issuer's registered direct offering of units, in which each unit consisted of one share of common stock and one common stock warrant to purchase 0.75 of a share of common stock, at a price of $4.00 per unit. The price paid per unit is reflected in Table I. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 17:17 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 123,333 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0000899243-21-026230 · doc4.xml · derivative · entry 2 Sullivan Lynne Marie · CIK 0001727640 · CFO & Head of Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,333 Underlying: Common Stock · 123,333 shares Expires 2031-06-23 F3 · derivative.exercise_date: Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 48-month period commencing on June 24, 2021 (the "Vesting Commencement Date"), so that 100% of the shares become fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 17:17 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantCommon Stock, $0.0001 par value | 30,833 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026230 · doc4.xml · nonDerivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · CFO & Head of Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,833 F1 · shares: Represents Restricted Stock Units ("RSUs") which vest in equal annual installments over a three year period measured from June 24, 2021. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F2 · balance_after: Includes RSUs which vest over time measured from the grant date. Read SEC document |
| June 23, 2021 Filed Jun 24, 2021 16:14 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantStock Option (right to buy) · Derivative | 9,367 | $0.00 Strike: $17.12 | $0.00 |
DisclosureSEC source: 0001209191-21-043008 · doc4.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,367 Underlying: Common Stock · 9,367 shares Expires 2031-06-22 F1 · derivative.exercise_date: The option was granted on June 23, 2021. The shares underlying the option are scheduled to vest as to 100% of the shares on June 23, 2022, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:00 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.94 | $0.00 |
DisclosureSEC source: 0001209191-21-041939 · doc4.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-06-16 F1 · derivative.exercise_date: This option was granted on June 16, 2021 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 20:27 UTC | Tessera Defense & Homeland Security Inc. PHGE · Entity 8384 | GrantCommon Stock Options - Right to Buy · Derivative | 15,200 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001213900-21-019664 · ownership.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,200 Underlying: Common Stock · 15,200 shares Expires 2031-03-30 F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 30, 2022, and the remainder vesting in 12 equal quarterly installments over three years. Read SEC document |
| September 13, 2020 Filed Sep 15, 2020 21:10 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantCommon Stock, $0.0001 par value | 240,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025187 · doc4.xml · nonDerivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 F1 · shares: Represents Restricted Stock Units ("RSUs") one-third of which vests on September 13, 2021 with the remaining RSUs vesting in equal quarterly installments over a two year period thereafter. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F1 · balance_after: Represents Restricted Stock Units ("RSUs") one-third of which vests on September 13, 2021 with the remaining RSUs vesting in equal quarterly installments over a two year period thereafter. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Read SEC document |
| August 01, 2020 Filed Aug 4, 2020 18:12 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 240,000 | $0.00 Strike: $9.96 | $0.00 |
DisclosureSEC source: 0000899243-20-021189 · doc4.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2030-07-31 F1 · derivative.exercise_date: The underlying shares vest and become exercisable pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vested on August 1, 2021 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| July 23, 2020 Filed Jul 24, 2020 16:43 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantStock Option (right to buy) · Derivative | 9,367 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-20-020390 · doc4.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,367 Underlying: Common Stock · 9,367 shares Expires 2030-07-22 F1 · derivative.exercise_date: The option was granted on July 23, 2020. The shares underlying the option are scheduled to vest as to 100% of the shares on July 23, 2021, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 20:23 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0001209191-20-037591 · doc4.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: This option was granted on June 16, 2020 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 20:32 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 14,414 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0000899243-20-015454 · doc4.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,414 Underlying: Common Stock · 14,414 shares Expires 2030-06-02 F1 · derivative.exercise_date: This option was granted on June 3, 2020 with respect to 14,414 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| March 25, 2020 Filed Mar 27, 2020 20:00 UTC | Tessera Defense & Homeland Security Inc. PHGE · Entity 8384 | GrantCommon Stock Options - Right to Buy · Derivative | 16,000 | $0.00 Strike: $6.21 | $0.00 |
DisclosureSEC source: 0001213900-20-007660 · ownership.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2030-03-25 F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 25, 2021, and the remainder vesting in 12 equal quarterly installments over three years. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 20:16 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $5.26 | $0.00 |
DisclosureSEC source: 0001209191-19-037127 · doc4.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-13 F1 · derivative.exercise_date: This option was granted on June 13, 2019 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| May 08, 2019 Filed May 9, 2019 22:51 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 14,414 | $0.00 Strike: $7.99 | $0.00 |
DisclosureSEC source: 0000899243-19-012926 · doc4.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,414 Underlying: Common Stock · 14,414 shares Expires 2029-05-07 F1 · derivative.exercise_date: This option was granted on May 8, 2019 with respect to 14,414 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 21:12 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 8,165 | $0.00 Strike: $23.58 | $0.00 |
DisclosureSEC source: 0000899243-18-031211 · doc4.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,165 Underlying: Common Stock · 8,165 shares Expires 2028-12-13 F1 · derivative.exercise_date: This option was granted on December 13, 2018 and vests in full on the earlier to occur of July 25, 2019 and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| July 25, 2018 Filed Jul 26, 2018 22:36 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,835 | $0.00 Strike: $37.89 | $0.00 |
DisclosureSEC source: 0000899243-18-020704 · doc4.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,835 Underlying: Common Stock · 1,835 shares Expires 2028-07-25 F1 · derivative.exercise_date: This option was granted on July 25, 2018 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.